Author:
Bradley Daniel P.,Wyant Tim
Reference77 articles.
1. Aboagye EO (2005) Positron emission tomography imaging of small animals in anticancer drug development. Mol Imaging Biol 7:53–58
2. Albanese C, Rodriguez OC, Vanmeter J, Fricke ST, Rood BR, Lee Y, Wang SS, Madhavan S, Gusev Y, Petricoin EF, 3rd, et al (2012) Preclinical magnetic resonance imaging and systems biology in cancer research: Current applications and challenges. Am J Pathol
3. Bahce I, Smit EF, Lubberink M, van der Veldt AA, Yaqub M, Windhorst AD, Schuit RC, Thunnissen E, Heideman DAH, Postmus PE et al (2013) Development of [11C]erlotinib positron emission tomography for in vivo evaluation of epidermal growth factor receptor mutational status. Clin Cancer Res Off J Am Assoc Cancer Res 19:183–193
4. Barnes SL, Whisenant JG, Loveless ME, Yankeelov TE (2012) Practical dynamic contrast enhanced MRI in small animal models of cancer: data acquisition, data analysis, and interpretation. Pharmaceutics 4:442–478
5. Baudelet C, Gallez B (2004) Effect of anesthesia on the signal intensity in tumors using BOLD-MRI: comparison with flow measurements by Laser Doppler flowmetry and oxygen measurements by luminescence-based probes. Magn Reson Imaging 22:905–912